Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind very-low-dose controlled study of XKZ2305 granules for mild to moderate acute exacerbation of pediatric bronchial asthma
CTR20263498Phase 2Active
- Sponsor
- 联成迅康
- Start
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of XKZ2305 granules in asthma, sponsored by 联成迅康. Started Sep 2026; status: active.
02
Drugs
XKZ2305 granules
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20263498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263498.